Arcus Biosciences, Inc. (NYSE:RCUS) announced that it has entered into a purchase agreement with returning investor Gilead Sciences, Inc. (NasdaqGS:GILD) for private placement of 5,650,000 shares at an issue price of $39 per share for gross proceeds of $220,350,000 on January 31, 2021. Post the closing, the investor's stake in the company will increase from approximately 13% to 19.5%. The transaction is subject to customary closing conditions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.67 USD | -2.79% | -9.11% | -17.96% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.96% | 1.43B | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+38.42% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- RCUS Stock
- News Arcus Biosciences, Inc.
- Arcus Biosciences, Inc. announced that it expects to receive $220.35 million in funding from Gilead Sciences, Inc.